Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Protalix BioTherapeutics (PLX) Interest Expenses (2016 - 2025)

Protalix BioTherapeutics (PLX) has 13 years of Interest Expenses data on record, last reported at $6000.0 in Q1 2025.

  • For Q1 2025, Interest Expenses fell 98.46% year-over-year to $6000.0; the TTM value through Sep 2025 reached $47000.0, down 97.37%, while the annual FY2024 figure was $1.1 million, 66.6% down from the prior year.
  • Interest Expenses reached $6000.0 in Q1 2025 per PLX's latest filing, down from $41000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $2.4 million in Q3 2021 and bottomed at $6000.0 in Q1 2025.
  • Average Interest Expenses over 5 years is $848000.0, with a median of $637000.0 recorded in 2022.
  • Peak YoY movement for Interest Expenses: skyrocketed 109.47% in 2023, then plummeted 98.46% in 2025.
  • A 5-year view of Interest Expenses shows it stood at $908000.0 in 2021, then decreased by 28.41% to $650000.0 in 2022, then rose by 17.85% to $766000.0 in 2023, then tumbled by 94.65% to $41000.0 in 2024, then crashed by 85.37% to $6000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $6000.0 in Q1 2025, $41000.0 in Q4 2024, and $260000.0 in Q3 2024.